OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed solid tumors that have been shown to overexpress clusterin, including but not limited to, any of the following:

  * Prostate cancer
  * Renal cell carcinoma
  * Non-small cell lung cancer
  * Bladder cancer
  * Breast cancer
  * Ovarian cancer
* Metastatic or locally recurrent disease
* Refractory to standard curative therapy or no standard curative therapy exists

  * Patients with prostate cancer must be hormone refractory (i.e., have documented evidence of progression while receiving androgen ablative therapy)
* Measurable or nonmeasurable disease

  * Measurable disease defined as measurable lesion ≥ 20 mm by x-ray, physical exam, or nonspiral CT scan or ≥ 10 mm by spiral CT scan
* No documented CNS metastases
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Menopausal status not specified
* ECOG performance status 0-2
* Life expectancy ≥ 12 weeks
* Absolute granulocyte count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Bilirubin normal
* Creatinine ≤ 2 times upper limit of normal (ULN)
* AST and ALT ≤ 1.5 times ULN
* PT/INR and PTT normal
* No uncontrolled pain
* No known bleeding disorder
* No history of serious allergic reaction to taxane (paclitaxel or docetaxel)
* No preexisting peripheral neuropathy ≥ grade 2
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No other serious illness or medical conditions that would preclude study compliance, including any of the following:

  * Active uncontrolled infection
  * Significant cardiac dysfunction
* No significant neurological disorder that would preclude giving informed consent

PRIOR CONCURRENT THERAPY:

* No prior strontium chloride Sr 89
* No more than 2 prior chemotherapy regimens, including adjuvant or neoadjuvant chemotherapy (for patients assigned to schedule B \[docetaxel once every 3 weeks\])
* More than 4 weeks since prior chemotherapy and recovered
* At least 4 weeks since prior antiandrogens
* More than 4 weeks since prior external-beam radiotherapy, except low-dose nonmyelosuppressive radiotherapy
* No prior radiotherapy to ≥ 30% of marrow-bearing areas (for patients assigned to schedule B \[docetaxel once every 3 weeks\])
* At least 28 days since prior new anticancer therapy
* At least 28 days since prior and no other concurrent investigational agents
* No concurrent radiotherapy, except low-dose nonmyelosuppressive radiotherapy
* No other concurrent cytotoxic therapy
* Concurrent luteinizing hormone-releasing hormone agonist allowed (if already initiated in patients with prostate cancer)
* No concurrent anticoagulant therapy (i.e., heparin, warfarin)